Reviva Pharmaceuticals Files 8-K

TL;DR

Reviva Pharma filed an 8-K on Nov 12, 2024. Standard update.

AI Summary

Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on November 12, 2024, reporting on other events and financial statements. The company, formerly Tenzing Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides an update on the company's corporate activities and financial reporting, which is crucial for investors to assess its current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information indicating significant new risks.

Key Players & Entities

• REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
• Tenzing Acquisition Corp. (company) — Former company name
• November 12, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share RVPH Nasdaq Capital Marke

Filing Documents

• rvph20241111_8k.htm (8-K) — 33KB
• ex_746295.htm (EX-99.1) — 18KB
• 0001437749-24-034338.txt ( ) — 203KB
• rvph-20241112.xsd (EX-101.SCH) — 4KB
• rvph-20241112_def.xml (EX-101.DEF) — 13KB
• rvph-20241112_lab.xml (EX-101.LAB) — 17KB
• rvph-20241112_pre.xml (EX-101.PRE) — 13KB
• rvph20241111_8k_htm.xml (XML) — 5KB

01

Item 7.01. Regulation FD Disclosure. On November 12, 2024, Reviva Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing an enrollment update to the RECOVER ongoing 1-year open label extension ("OLE") study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01

Item 8.01. Other Events. On November 12, 2024, the Company announced the following enrollment status update for the OLE study: Global trial progressing well 108 patients have completed 1-year (12-month) of treatment Over 250 patients have completed 6-months of treatment Blood and digital biomarkers designed to independently support efficacy Long-term safety data from 100 patients who have completed 12 months of treatment is a requirement for brilaroxazine's NDA submission to the FDA 12 months long-term safety study to complete in Q1 2025

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated November 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Dated: November 12, 2024 By: /s/ Narayan Prabhu Name: Title: Narayan Prabhu Chief Financial Officer